Mahamaya Lifesciences Ltd

Mahamaya Lifesc. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mahamaya Lifesciences Ltd

₹ 138 0.58%
12 Dec - close price
mahamayalifesciences.com/home BSE - SME: 544611
About

ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]

Key Points

Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.

Website BSE
  • Market Cap ₹ 323 Cr.
  • Current Price ₹ 138
  • High / Low ₹ 151 / 111
  • Stock P/E 23.0
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE 25.9 %
  • ROE 34.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.5%

Cons

  • Debtor days have increased from 52.1 to 67.0 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals

Part of BSE SME IPO

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2024 Sep 2025
146 163
133 148
Operating Profit 13 15
OPM % 9% 9%
1 1
Interest 4 4
Depreciation 1 1
Profit before tax 10 11
Tax % 27% 27%
7 8
EPS in Rs 4.08 4.71
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
90 137 161 264
84 128 148 241
Operating Profit 6 9 13 23
OPM % 7% 6% 8% 9%
0 0 1 3
Interest 2 3 6 7
Depreciation 1 1 1 2
Profit before tax 4 5 7 17
Tax % 27% 26% 27% 25%
3 4 5 13
EPS in Rs 21.78 30.03 41.80 7.28
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 43%
TTM: 63%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 68%
TTM: 149%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 29%
Last Year: 35%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 1 1 1 18 18
Reserves 14 18 23 32 40
19 24 55 58 68
21 34 33 81 110
Total Liabilities 56 78 112 188 236
20 21 21 27 31
CWIP 2 2 3 4 0
Investments 0 0 0 0 0
34 54 88 157 205
Total Assets 56 78 112 188 236

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
2 1 -23 1
-3 -3 -2 -8
1 2 24 9
Net Cash Flow 0 1 -0 1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 37 25 64 67
Inventory Days 93 109 137 167
Days Payable 83 87 61 92
Cash Conversion Cycle 47 48 140 142
Working Capital Days 8 9 14 29
ROCE % 20% 21% 26%

Shareholding Pattern

Numbers in percentages

4 Recently
Nov 2025
56.35%
6.39%
4.67%
32.60%
No. of Shareholders 1,034

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.